Abstract
AbstractNon-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that is becoming increasingly prevalent, and it ranges from simple steatosis to cirrhosis. However, there is still a lack of pharmacotherapeutic strategies approved by the Food and Drug Administration, which results in a higher risk of death related to carcinoma and cardiovascular complications. Of note, it is well established that the pathogenesis of NAFLD is tightly associated with whole metabolic dysfunction. Thus, targeting interconnected metabolic conditions could present promising benefits to NAFLD, according to a number of clinical studies. Here, we summarize the metabolic characteristics of the development of NAFLD, including glucose metabolism, lipid metabolism and intestinal metabolism, and provide insight into pharmacological targets. In addition, we present updates on the progresses in the development of pharmacotherapeutic strategies based on metabolic intervention globally, which could lead to new opportunities for NAFLD drug development.
Funder
National Natural Science Foundation of China
Shanghai Rising-Star Program
Lingang Laboratory
China National Postdoctoral Program for Innovative Talents
China Postdoctoral Science Foundation
Shanghai Sixth People’s Hospital
National Key R&D Program of China
Shanghai Municipal Commission of Science and Technology
National Facility for Translational Medicine
Shanghai Municipal Education Commission
Training Program of the Major Research Plan of the National Natural Science Foundation
Innovative research team of high-level local universities in Shanghai
Publisher
Springer Science and Business Media LLC
Subject
Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)